Recently, the DAPA-HF study was conducted to determine effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes [61••]. Here, SLC5A2 is linked to type 2 diabetes mellitus.